NO-1886
NO-1886 性质
| 熔点 | 160.5-162.1 °C |
|---|---|
| 沸点 | 512.5±50.0 °C(Predicted) |
| 密度 | 1.44±0.1 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | 二甲基亚砜：≥20mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 11.51±0.70(Predicted) |
| 颜色 | 灰白色至浅黄色 |
NO-1886 用途与合成方法
Lipoprotein lipase (LPL)
Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at translational levels in a dose-dependent and time-dependent manner .
Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner .
Ibrolipim 5 and 50 μmol/L significantly increases cholesterol efflux from THP-1 macrophage-derived foam cells to apoA-I or HDL. LXRα is also upregulated by the Ibrolipim treatment. LXRα small interfering RNA completely abolishes the promotion effect that is induced by Ibrolipim.
Western Blot Analysis
| Cell Line: | THP-1 macrophage-derived foam cells |
| Concentration: | 0.5 μM, 5 μM, 10 μM |
| Incubation Time: | 0 hour, 6 hours, 12 hours, 24 hours |
| Result: | Increased ABCA1 and ABCG1 translational levels in a dose-dependent and time-dependent manner. |
RT-PCR
| Cell Line: | THP-1 macrophage-derived foam cells |
| Concentration: | 0.5 μM, 5 μM, 10 μM |
| Incubation Time: | 0 hour, 6 hours, 12 hours, 24 hours |
| Result: | Increased ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner. |
Ibrolipim (NO-1886; 100 mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue.
| Animal Model: | Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; daily; for 8 weeks |
| Result: | Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy. |
NO-1886 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-117549 | 1 mg | 200 | ||
| 2024-04-30 | HY-117549 | NO-1886 | 133208-93-2 | 5mg | 400 |
